Quidelortho Corp (QDEL) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Quidelortho Corp (QDEL) stock forecast summary
On Oct. 14, 2026, QDEL is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Quidelortho Corp is a small-cap company with a market capitalization of $967M. It ranks number 6 by market capitalization among the 15 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its P/B Ratio of 0.54x is the lowest of the 11 peers that report one. Its D/E Ratio of 2.22x is the highest of the 12 peers that report one.
A per-ticker accuracy statistic for QDEL is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, QDEL included.
Follow QDEL freeQDEL price chart and AI forecast
How QDEL ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Quidelortho Corp (QDEL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | QDEL | Rank |
|---|---|---|
| Market Cap | $967M | 6/15 |
| P/B Ratio | 0.54x | 11/11 |
| EPS | $-15.44 | – |
| Book Value/Share | $25.88 | – |
| Revenue/Share | $39.00 | – |
| FCF/Share | $-4.19 | – |
Profitability & Margins
| Metric | QDEL | Rank |
|---|---|---|
| ROE | -59.1% | 9/11 |
| ROA | -18.3% | 7/13 |
| ROIC | -17.5% | 5/11 |
| Gross Margin | 44.6% | 6/9 |
| Operating Margin | -30.8% | 6/14 |
| Net Margin | -39.2% | 7/11 |
| EBT Margin | -38.5% | 7/14 |
| Tax Rate | -1.8% | – |
Financial Health
| Metric | QDEL | Rank |
|---|---|---|
| Current Ratio | 1.39x | 11/15 |
| Quick Ratio | 0.76x | 8/9 |
| D/E Ratio | 2.22x | 1/12 |
| Financial Leverage | 3.22x | 1/12 |
| Interest Coverage | -0.4x | 8/14 |
| Working Capital | $383M | 5/15 |
Cash Flow
| Metric | QDEL | Rank |
|---|---|---|
| Operating Cash Flow | -$156M | 14/16 |
| Free Cash Flow | -$288M | 9/10 |
| Capital Spending | -$132M | 10/10 |
| OCF Growth YoY | -158.4% | 5/5 |
| FCF Growth YoY | -422.4% | – |
| FCF/Sales | -10.8% | 4/10 |
| CapEx/Sales | 4.9% | 5/10 |
Operational Efficiency
| Metric | QDEL | Rank |
|---|---|---|
| Asset Turnover | 0.47x | 5/12 |
| Receivables Turnover | 7.6x | 6/11 |
| Inventory Turnover | 2.4x | 8/9 |
| Fixed Assets Turnover | 2.0x | 6/12 |
| Days Sales Outstanding | 48 days | 6/11 |
| Days Inventory | 152 days | 2/9 |
| Payables Period | 58 days | 4/9 |
| Cash Conversion Cycle | 142 days | 2/8 |
Income Statement
| Metric | QDEL | Rank |
|---|---|---|
| Total Revenue | $2.67B | 2/12 |
| Operating Income | -$824M | 15/15 |
| Net Income | -$1.05B | 13/13 |
| R&D Expense | $181M | 4/16 |
| SG&A Expense | $770M | 2/12 |
| Cost of Goods Sold | $1.48B | 2/10 |
Dividend & Shareholder Information
| Metric | QDEL | Rank |
|---|---|---|
| Shares Outstanding | 69M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.38B | 24.1% of assets |
| Cash & Short-term Investments | $123M | 2.2% of assets |
| Accounts Receivable | $352M | 6.2% of assets |
| Inventory | $619M | 10.8% of assets |
| Total Liabilities | $3.94B | 68.9% of assets |
| Short-term Debt | $757M | 13.2% of assets |
QDEL quarterly financials and insider trading
Quidelortho Corp (QDEL) industry peers
Companies classified under the same SEC industry code as Quidelortho Corp (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| QDEL Quidelortho Corp | ▶ | $967M |
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B |
| NEOG Neogen Corp | ▲ | $2.56B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B |
| ACHV Achieve Life Sciences, Inc. | ▶ | $720M |
| TKNO Alpha Teknova, Inc. | ▲ | $441M |
| MYGN Myriad Genetics Inc | ▲ | $390M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▲ | $87M |
| AWHL Aspira Women's Health Inc. | ▲ | $12M |
| BMRA Biomerica Inc | ▲ | $8M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▶ | $5M |
| VNRX Volitionrx Ltd | ▼ | $3M |
| QCLS Q/C Technologies, Inc. | ▼ | N/A |
| TRIB Trinity Biotech Plc | ▼ | N/A |
Where QDEL sits on the market map
Quidelortho Corp (QDEL) stock news
Loading...
Quidelortho Corp (QDEL) stock forecast FAQ
What is the Quidelortho Corp (QDEL) stock forecast?
On Oct. 14, 2026, QDEL is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Quidelortho Corp stock predictions?
A per-ticker accuracy statistic for QDEL is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Quidelortho Corp forecasts updated?
Quidelortho Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Quidelortho Corp's industry peers?
17 issuers in our coverage, QDEL included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Achieve Life Sciences, Inc. (ACHV).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.